Percutaneous Renal Tumor Cryoablation Effect on Renal Function

Area of Science:

• Nephrology
• Urology
• Oncology

Background:

• Percutaneous cryoablation (PCA) is an established treatment for renal tumors.
• Limited data exists on the long-term renal function post-PCA.
• Evaluating renal function is crucial for assessing treatment safety and efficacy.

Purpose of the Study:

• To assess the effects of computed tomography-guided PCA on renal function.
• To evaluate changes in estimated glomerular filtration rate (eGFR) 12 months after PCA.

Main Methods:

• Retrospective cohort study of 259 patients undergoing PCA for renal tumors.
• Collected baseline and 12-month follow-up eGFR data.
• Analyzed eGFR changes in relation to chronic kidney disease (CKD) stages.

Main Results:

• Mean eGFR showed a minimal decline from 73.7 to 69.7 mL/min/1.73 m² (p < 0.0001) at 12 months.
• Most patients maintained or had minimal changes in their CKD stage.
• No significant eGFR decline was observed in patients with skewed renography treated in the better-functioning kidney.

Conclusions:

• PCA demonstrates minimal adverse effects on renal function one year after treatment.
• The procedure is considered safe and relevant for managing renal tumors, including in patients with impaired renal function.